AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
AYTU BIOPHARMA, INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
AYTU BIOPHARMA, INC revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RX Segment [Member] | $57.57M | $66.38M | – | – | – | – | – | – | – | – | 100.0% | -13.3% |
| Consumer Health [Member] | – | – | $15.82M | $33.60M | $35.55M | $32.95M | – | – | – | – | – | – |
| Rx | – | – | – | $73.80M | $61.12M | – | – | – | – | – | – | – |
| Rx Segment [Member] | – | $66.38M | $65.18M | $73.80M | – | – | – | – | – | – | – | – |
| Aytu [Member] | – | – | – | – | – | – | – | – | $3.42M | $3.18M | – | – |
| Aytu Women's Health [Member] | – | – | – | – | – | – | – | – | $243.00K | $47.00K | – | – |
| Aytu BioScience | – | – | – | – | – | – | $17.25M | $7.32M | – | – | – | – |
| Aytu Consumer Health | – | – | – | – | – | $32.95M | $10.38M | $0 | – | – | – | – |
| Aytu BioPharma | – | – | – | – | – | $32.68M | $17.25M | – | – | – | – | – |
| BioPharma | – | – | – | – | $61.12M | $32.68M | – | – | – | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Health [Member] | – | – | -$3.66M | -$9.71M | -$17.47M | – | – | – | – | – | – |
| Rx | – | – | – | -$7.36M | -$92.44M | – | – | – | – | – | – |
| Rx Segment [Member] | – | – | -$1.59M | -$7.36M | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | – | – | – | – | – | – | $27.63M | $7.31M | – | – | – | – |
| License Revenue | – | – | – | – | – | – | $0 | $5.78K | – | – | – | – |
| Consumer Health Portfolio | – | – | – | – | $35.55M | $32.95M | $10.38M | $0 | – | – | – | – |
| Pediatric | – | – | – | $25.38M | $16.08M | $12.44M | $9.29M | – | – | – | – | – |
| Primary Care and Devices Portfolio | – | – | – | – | – | $8.25M | $7.96M | – | – | – | – | – |
| Other Product Portfolio | – | – | – | – | $2.18M | $9.36M | – | – | – | – | – | – |
| ADHD | – | – | – | $46.86M | $42.86M | $10.88M | – | – | – | – | – | – |
| Other | – | – | – | $1.57M | $2.18M | – | – | – | – | – | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | $80.91M | $106.92M | $94.61M | $60.69M | $24.98M | $6.46M | $3.21M | – | – | – |
| Rest-of-the-World | – | – | – | – | – | – | $2.65M | $858.00K | $447.00K | – | – | – |
| Non-US [Member] | – | – | $91.00K | $481.00K | $2.06M | $4.95M | $2.65M | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Aytu Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.